

NOVAVAX INC
Form 8-K
August 08, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT UNDER SECTION 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 8, 2003

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-26770

22-2816046

(State or other jurisdiction of
incorporation or organization)

(Commission
File No.)

(I.R.S. Employer
Identification No.)

8320 Guilford Road, Columbia, MD

21046

(Address of principal executive offices)

(Zip code)

(301) 854-3900

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT

ITEM 5. OTHER EVENTS.

On August 8, 2003, the Company announced the appointment of Nelson M. Sims as President and Chief Executive Officer and Director of Novavax, Inc.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

ITEM 7. EXHIBITS.

99.1 Press Release dated August 8, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVAVAX, INC.

Date: August 8, 2003

By: /s/ Dennis W. Genge

Dennis W. Genge, Vice President and
Chief Financial Officer/Treasurer